What BUILT Biotechnologies does

BUILT Biotechnologies, Inc. (operating as BUILT DNA) is a Charlottesville, Virginia-based DNA manufacturing-as-a-service company founded in 2023. The company addresses what its CEO calls the 'last mile of DNA supply': customers submit sequences through a direct online ordering portal and receive sequence-perfect, fully verified DNA molecules. BUILT serves primarily biotechnology researchers and companies working in genome engineering, synthetic biology, mRNA/saRNA production, and high-throughput discovery.

The company's core technology is its proprietary Regenerative DNA Assembly™ platform, which is paired with an ever-growing BUILT DNA Inventory of validated DNA fragments. Rather than building every construct from scratch, the platform reuses pre-validated fragments, which the company states enables faster and more cost-effective delivery while preserving sequence accuracy. The architecture underpins four turnkey product categories: clonal plasmid DNA delivered in the Standard BUILT Backbone (SBB); Whole-Plasmid Synthesis (WPS) for de novo plasmid construction; Sequence-Perfect Linear DNA (LD) intended as IVT templates for mRNA and saRNA production; and Pooled Plasmid Libraries (PPL) for high-throughput discovery applications. Trademarks are registered for Regenerative DNA Assembly™, Fully BUILT DNA™, and Standard BUILT Backbone.

BUILT's business model is transactional product sales: customers order manufactured DNA via an Atlassian-based customer portal at quote-based pricing that is not publicly disclosed. The go-to-market motion is sales-led, combining the direct ordering portal with a selective Early Access Program targeting innovator-partners and a membership in the Commonwealth BioAccelerator at North Fork Research Park for ecosystem visibility. The leadership team consists of CEO George McArthur, PhD, and a Chief Commercial Officer / CXO. The company reports onboarding more than 50 new customers in the genome engineering segment and was named preferred DNA manufacturing partner for Neochromosome's transitioning client base in November 2025, with service continuity through early 2026. Headcount sits in the 1-10 range.

Name

BUILT Biotechnologies

Legal name

Built Biotechnologies, Inc.

Website

https://builtdna.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

BUILT Biotechnologies operates a DNA manufacturing-as-a-service platform based in Charlottesville, VA. Using its proprietary Regenerative DNA Assembly technology and a validated DNA fragment inventory, the company ships sequence-perfect plasmids, linear DNA, and pooled libraries to biotech and genome engineering customers.

Ownership category

akta.pro rank

Product category

DNA Manufacturing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• DNA manufacturing services
• Synthetic biology
• Plasmid DNA production
• Genome engineering
• DNA assembly

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. DNA Manufacturing Services: BUILT manufactures and sells four types of DNA products: clonal plasmid DNA, whole-plasmid synthesis, linear DNA, and pooled plasmid libraries. Customers submit sequences and receive ready-to-use molecules, representing a transactional product-based revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BUILT Biotechnologies provides DNA manufacturing-as-a-service using its proprietary Regenerative DNA Assembly platform. Customers submit DNA sequences and receive ready-to-use, sequence-perfect DNA molecules across four product types: Clonal plasmid DNA in the Standard BUILT Backbone (SBB), Whole-Plasmid Synthesis (WPS), Sequence-Perfect Linear DNA (LD) for IVT templates, and Pooled Plasmid Libraries (PPL) for high-throughput discovery.

Product overview

BUILT Biotechnologies operates as a DNA manufacturing platform offering four turnkey product types built on its Regenerative DNA Assembly™ technology and the BUILT DNA Inventory. The platform produces sequence-perfect DNA including: Clonal plasmid DNA in the Standard BUILT Backbone (SBB) for verified vectors, Whole-Plasmid Synthesis (WPS) for building plasmids from scratch, Sequence-Perfect Linear DNA (LD) for mRNA/saRNA IVT templates, and Pooled Plasmid Libraries (PPL) for high-throughput discovery. Customers submit sequences and receive ready-to-use molecules. The company also offers an Early Access Program for select innovation partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Standard BUILT Backbone (SBB) - Clonal Plasmid DNA Sequence-perfect, fully verified clonal plasmid DNA vectors ready for immediate use in downstream applications; intended for biotech researchers and genome engineering customers.
• Whole-Plasmid Synthesis (WPS) Build entire plasmid sequences from the ground up, providing complete, ready-to-use plasmid molecules for customers who need custom plasmid construction.
• Sequence-Perfect Linear DNA (LD) Linear DNA constructs ideal as IVT (in vitro transcription) templates for mRNA and saRNA production, targeted at therapeutic and vaccine developers.
• Pooled Plasmid Libraries (PPL) Dense, diversity-rich collections of plasmids designed for high-throughput discovery applications in synthetic biology and genome engineering.
• Fully BUILT DNA Manufacturing Service End-to-end DNA manufacturing service: customers send sequences and BUILT ships sequence-perfect, fully verified ready-to-use DNA molecules across its four product types, fast and cost-effectively.
• Early Access Program Partnership-based DNA manufacturing access program for select early adopters who want to use BUILT's platform and help refine it for their research needs.

Quantifiable outcome

• Seamless service continuation for affected clients through early 2026

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• NeochromosomecoreGTM or Marketing Partner · 17 November 2025BUILT was chosen as the preferred DNA manufacturing partner for Neochromosome's clients. Neochromosome is transitioning their DNA construction projects to BUILT's platform as they shift focus to other platforms. The collaboration ensures seamless service continuation for affected clients through early 2026, representing a significant customer migration and ongoing service relationship.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Eurofins Genomics: Eurofins Genomics is a large-scale provider of genomic services including gene synthesis, plasmid preparation, and DNA sequencing. It competes with BUILT on plasmid manufacturing services but operates as part of a much broader life sciences testing portfolio.
• Thermo Fisher Scientific (GeneArt): Thermo Fisher offers GeneArt gene synthesis and molecular biology services as part of its life sciences portfolio. While not a focused DNA manufacturing specialist, it competes with BUILT for biotech research customers seeking plasmid and gene synthesis services.

Emerging players

• Ansa Biotechnologies: Ansa Biotechnologies is developing a novel enzymatic DNA synthesis approach targeting long, high-fidelity oligonucleotide production. It is an emerging competitor that could intersect with BUILT's DNA manufacturing platform as the technology matures.
• ATUM (formerly DNA2.0): ATUM is a synthetic biology company offering gene synthesis, plasmid construction, and protein engineering services. It directly overlaps with BUILT's plasmid DNA and whole-plasmid synthesis offerings for biotech customers.
• DNA Script: DNA Script is developing enzymatic DNA synthesis technology for on-demand oligonucleotide and gene production. While focused on the upstream synthesis step, it represents an emerging alternative platform that could overlap with BUILT's downstream manufacturing use cases.

Direct peers

• Integrated DNA Technologies (IDT): IDT, a Danaher company, is a premier provider of custom DNA and RNA oligonucleotides, gene synthesis, and IVT template production. It is a direct competitor to BUILT in the 'last-mile' DNA supply category, particularly for linear DNA and gene synthesis workflows.
• Synthego: Synthego provides synthetic biology solutions including gene synthesis, CRISPR reagents, and RNA manufacturing. It overlaps directly with BUILT's plasmid and linear DNA offerings and targets the same genome engineering customer segment.
• Twist Bioscience: Twist Bioscience is a leading DNA synthesis provider offering gene fragments, clonal genes, and pooled libraries on a silicon-based synthesis platform. It directly competes with BUILT across plasmid DNA, whole-plasmid synthesis, and pooled library offerings, and is the most relevant scaled competitor.
• GenScript: GenScript is a major gene synthesis and molecular biology services provider, offering custom plasmid construction, gene synthesis, and IVT template production. It competes head-to-head with BUILT's plasmid and linear DNA manufacturing services for biotech research customers.
• Telesis Bio (formerly Codex DNA): Telesis Bio develops automated DNA and mRNA synthesis platforms, including the BioXp system for on-demand gene and mRNA production. It competes with BUILT in the plasmid DNA and IVT template manufacturing space, particularly for researchers seeking rapid turnaround.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BUILT Biotechnologies